Type 2 diabetes
Conditions
Interventions
We evaluate glycemic dynamics for 14 days with flash glucose monitoring (FGM) in patients with type 2 diabetes receiving 1000 mg/day of metformin. First half of observation period (Day 1-7): Metformi
Sponsors
Tonami general hospital Department of diabetes mellitus and endocrinology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetes Administration of metformin 1000 mg/day eGFR 45ml/min/1.73m2<=
Exclusion criteria
Exclusion criteria: 1. Patients with a history of hypersensitivity to metformin components or biguanide drugs 2. Patients with a history of lactic acidosis 3. Patients with severe renal dysfunction or dialysis patients 4. Patients with severe liver dysfunction 5. Patients with severely impaired cardiovascular system or pulmonary function and other patients who are prone to hypoxemia 6. Patients with dehydration or suspected dehydration 7. Excessive alcohol drinkers 8. Patients with severe ketosis, diabetic coma or pre-coma, or type 1 diabetes 9. Patients with severe infection, before and after surgery, and serious trauma 10. Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal insufficiency 11. Pregnant women, women who may be pregnant, or women who are breast-feeding 12.Other cases judged by the investigator to be inappropriate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour average blood glucose, fasting blood glucose, SD and CV. | — |
Secondary
| Measure | Time frame |
|---|---|
| TIR(time in range), TAR(time above range), TBR(time below range), MAGE(mean amplitude of glucose excursion), maximum blood glucose level, minimum blood glucose level and safety. | — |
Countries
Japan
Contacts
Public ContactKen-ichiro Kato
Tonami general hospital Department of diabetes mellitus and endocrinology
Outcome results
None listed